共 50 条
- [41] UFT plus leucovorin (LV) in advanced colorectal cancer (CCR).: A phase II trial.EUROPEAN JOURNAL OF CANCER, 1999, 35 : S79 - S79Aranda, EAntón-Torres, ASastre, JNavarro, MRivera, FCarrato, ABretón, JJGrávalos, CAparicio, JFernandez-Martos, CDíaz-Rubio, E
- [42] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603Hoff, Paulo M.Hochhaus, AndreasPestalozzi, Bernhard C.Tebbutt, Niall C.Li, JinKim, Tae WonKoynov, Krassimir D.Kurteva, GalinaPinter, TamasCheng, Yingvan Eyll, BrigittePike, LauraFielding, AnitraRobertson, Jane D.Saunders, Mark P.
- [43] Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Conroy, ThierryGalais, Marie-PierreRaoul, Jean LucBouche, OlivierGourgou-Bourgade, SophieDouillard, Jean-YvesEtienne, Pierre-LucBoige, ValerieMartel-Lafay, IsabelleMichel, PierreLlacer-Moscardo, CarmenBerille, JocelyneBedenne, LaurentAdenis, Antoine
- [44] FOLFOX / Bevacizumab (Beva) plus /- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)ANNALS OF ONCOLOGY, 2016, 27Schmoll, H. J.Garlipp, B.Junghanss, C.Leithauser, M.Vogel, A.Schaefers, M.Kaiser, U.Hoeffkes, H. G.Florschuetz, A.Ruessel, J.Kanzler, S.Edelmann, T.Forstbauer, H.Goehler, T.Hannig, C.Hildebrandt, B.Steighardt, J.Meinert, F. M.Cygon, F.Stein, A.
- [45] Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III TrialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) : 1341 - 1347Carrato, AlfredoSwieboda-Sadlej, AnnaStaszewska-Skurczynska, MarzannaLim, RobertRoman, LasloShparyk, YaroslavBondarenko, IgorJonker, Derek J.Sun, YanDe la Cruz, Jhony A.Williams, J. AndrewKorytowsky, BeataChristensen, James G.Lin, XunTursi, Jennifer M.Lechuga, Maria J.Van Cutsem, Eric
- [46] SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximabJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)Crosby, ThomasHurt, ChrisFalk, StephenGollins, SimonMukherjee, SomnathStaffurth, JohnRay, RubyBridgewater, John A.Geh, IanCunningham, DavidMaughan, TimGriffiths, Gareth
- [47] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158SHeinemann, V.Von Weikersthal, L. FischerMoosmann, N.Vehling-Kaiser, U.Stauch, M.Oruzio, D.Schulze, M.Walther, J.Weiss, J.Dietzfelbinger, H.
- [48] A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal CancerCLINICAL COLORECTAL CANCER, 2010, 9 (02) : 102 - 107Boccia, Ralph V.Cosgriff, Thomas M.Headley, David L.Badarinath, SuprithDakhil, Shaker R.
- [49] Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Kim, Tae WonMuro, KeiXu, Rui-huaPark, Young SukWang, WeiHan, Sae-WonOta, MitsuyoshiAhn, Joong BaeDeng, YanhongAkiyoshi, KoheiCho, Sang HeeBa, YiDenda, TadamichiLee, Keun-WookZhang, TaoMatsuda, ChuYamada, YasuhideMorita, SatoshiIwasa, SatoruSakamoto, Junichi
- [50] POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Lin, RongboChen, YiguiZhu, JinfengLin, PeichengChen, WujinFang, WenzhengLi, HuiLiu, JieZhao, ShenFan, Nan-Feng